期刊
GENES
卷 12, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/genes12040502
关键词
ribosome biogenesis; nucleolus; RNA Polymerase I; rRNA synthesis; breast cancer
资金
- NSF GRFP
- CSC-Yale World Scholars
- [R35GM131687]
Ribosome biogenesis is dysregulated in cancer cells, making it a potential target for therapy. Novel drugs targeting rDNA transcription machinery offer a promising avenue for breast cancer treatment.
Ribosome biogenesis is a complex process that is responsible for the formation of ribosomes and ultimately global protein synthesis. The first step in this process is the synthesis of the ribosomal RNA in the nucleolus, transcribed by RNA Polymerase I. Historically, abnormal nucleolar structure is indicative of poor cancer prognoses. In recent years, it has been shown that ribosome biogenesis, and rDNA transcription in particular, is dysregulated in cancer cells. Coupled with advancements in screening technology that allowed for the discovery of novel drugs targeting RNA Polymerase I, this transcriptional machinery is an increasingly viable target for cancer therapies. In this review, we discuss ribosome biogenesis in breast cancer and the different cellular pathways involved. Moreover, we discuss current therapeutics that have been found to affect rDNA transcription and more novel drugs that target rDNA transcription machinery as a promising avenue for breast cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据